BLT 0.00% 2.6¢ benitec biopharma limited

CAR-T, page-2

  1. 536 Posts.
    lightbulb Created with Sketch. 1
    Looks like David Suhy focusing on a bolton strategy is the right move for CAR-T

    "Would fit into GILD's stated strategy: With the company less focused on additional
    transformational deals at the moment and recently applying greater emphasis on bolstering
    their new cell therapy platform through, as management has noted, potential interest and bolton’s
    such as cell switching or gene-editing, we believe that Cell Design Labs fits well into GILD’s
    approach."
 
watchlist Created with Sketch. Add BLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.